Related Experiment Video
Updated: Jul 7, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
JAK2 activation in myeloproliferative neoplasms: a potential role for heterodimeric receptors
1H. Lee Moffitt Cancer Center, Tampa, Florida 33612, USA. gary.reuther@moffitt.org
Abstract:
The various roles and importance of JAK2 in cell signaling have been appreciated for some time. In 2005, a point mutation in JAK2 (JAK2-V617F) was identified in a number of neoplastic myeloproliferative disorders, ushering in a new era of JAK2 research. This discovery uncovered a new therapeutic target to treat these neoplasms and in turn possibly prevent their progression into cancer. A thorough understanding of the mechanism of JAK2-V617F-mediated activation will enhance our knowledge of how JAK2 contributes to these diseases. While mutationally activated, JAK2-V617F still requires homodimeric cytokine receptors to provide a scaffold upon which the JAK2 molecules trans-activate each other via phosphorylation. We have recently shown that in addition to homodimeric receptors, single components of heterodimeric cytokine receptors may substitute for homodimeric receptors in activation of this mutant JAK2. While mutations in homodimeric cytokine receptors have been found in JAK2-negative myeloproliferative neoplasms, it is possible that components of heterodimeric receptors also contribute to these disorders through aberrant expression or mutational activation.
Insights
The Janus kinase 2 (JAK2)-V617F mutation is crucial in myeloproliferative neoplasms. This study reveals that heterodimeric cytokine receptors, not just homodimeric ones, can activate mutant JAK2, offering new therapeutic insights.
Area of Science:
- Molecular Biology
- Cell Signaling
- Oncology
Background:
- The Janus kinase 2 (JAK2) plays a significant role in cellular signaling pathways.
- A specific point mutation, JAK2-V617F, identified in 2005, is implicated in various myeloproliferative neoplasms (MPNs).
- This mutation presents a potential therapeutic target for MPNs and their progression to cancer.
Purpose of the Study:
- To elucidate the precise mechanism of JAK2-V617F-mediated activation.
- To understand the contribution of JAK2 to the pathogenesis of MPNs.
- To explore the role of cytokine receptors in JAK2 activation.
Main Methods:
- Investigated the role of homodimeric and heterodimeric cytokine receptors in JAK2-V617F activation.
- Analyzed the mechanism of JAK2 trans-activation via phosphorylation.
- Examined potential contributions of receptor components in JAK2-negative MPNs.
Main Results:
- Mutationally activated JAK2-V617F requires cytokine receptors for trans-activation.
- Both homodimeric and single components of heterodimeric cytokine receptors can serve as scaffolds for JAK2-V617F activation.
- Aberrant expression or mutation of heterodimeric receptor components may contribute to JAK2-negative MPNs.
Conclusions:
- The activation mechanism of JAK2-V617F involves cytokine receptor scaffolds.
- Heterodimeric cytokine receptors represent a novel pathway for JAK2 activation in MPNs.
- Further research into heterodimeric receptor components could reveal new therapeutic strategies for MPNs.
More Related Videos
11:55Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
Published on: March 14, 2011
07:38Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Related Concept Videos
The JAK-STAT Signaling Pathway
Receptor Tyrosine Kinases
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Differentiation of Common Myeloid Progenitor Cells
cAMP-dependent Protein Kinase Pathways